386 related articles for article (PubMed ID: 29246243)
1. The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs.
Cho SK; Lee J; Han M; Bae SC; Sung YK
Arthritis Res Ther; 2017 Dec; 19(1):277. PubMed ID: 29246243
[TBL] [Abstract][Full Text] [Related]
2. Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study.
Ozen G; Pedro S; Schumacher R; Simon TA; Michaud K
Arthritis Res Ther; 2019 Jun; 21(1):141. PubMed ID: 31174592
[TBL] [Abstract][Full Text] [Related]
3. Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort study.
Buchbinder R; Van Doornum S; Staples M; Lassere M; March L
BMC Musculoskelet Disord; 2015 Oct; 16():309. PubMed ID: 26481039
[TBL] [Abstract][Full Text] [Related]
4. Risk of malignancy in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under immunosuppressive therapy: a single-center experience.
Fantò M; Peragallo MS; Pietrosanti M; Di Rosa R; Picchianti Diamanti A; Salemi S; D'Amelio R
Intern Emerg Med; 2016 Feb; 11(1):31-40. PubMed ID: 26099279
[TBL] [Abstract][Full Text] [Related]
5. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis.
Simon TA; Thompson A; Gandhi KK; Hochberg MC; Suissa S
Arthritis Res Ther; 2015 Aug; 17(1):212. PubMed ID: 26271620
[TBL] [Abstract][Full Text] [Related]
6. Comparisons between comorbid conditions and health care consumption in rheumatoid arthritis patients with or without biological disease-modifying anti-rheumatic drugs: a register-based study.
Bengtsson K; Jacobsson LT; Rydberg B; Kvist G; Torstenson T; Dehlin M; Hilme E; Lindhé A; Wallerstedt SM; Forsblad-d'Elia H
BMC Musculoskelet Disord; 2016 Dec; 17(1):499. PubMed ID: 27955647
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry.
Gabay C; Riek M; Scherer A; Finckh A;
Rheumatology (Oxford); 2015 Sep; 54(9):1664-72. PubMed ID: 25922549
[TBL] [Abstract][Full Text] [Related]
8. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis.
Setoguchi S; Solomon DH; Weinblatt ME; Katz JN; Avorn J; Glynn RJ; Cook EF; Carney G; Schneeweiss S
Arthritis Rheum; 2006 Sep; 54(9):2757-64. PubMed ID: 16947774
[TBL] [Abstract][Full Text] [Related]
9. Risk of virus-associated cancer in female arthritis patients treated with biological DMARDs-a cohort study.
Cordtz R; Mellemkjær L; Glintborg B; Hetland ML; Madsen OR; Jensen Hansen IM; Dreyer L
Rheumatology (Oxford); 2016 Jun; 55(6):1017-22. PubMed ID: 26912584
[TBL] [Abstract][Full Text] [Related]
10. Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer.
Pundole X; Zamora NV; Siddhanamatha H; Lin H; Tayar J; Hong LC; Li L; Suarez-Almazor ME
Clin Rheumatol; 2020 Mar; 39(3):787-794. PubMed ID: 31853733
[TBL] [Abstract][Full Text] [Related]
11. Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: A nationwide cohort study in Japan.
Harigai M; Nanki T; Koike R; Tanaka M; Watanabe-Imai K; Komano Y; Sakai R; Yamazaki H; Koike T; Miyasaka N
Mod Rheumatol; 2016 Sep; 26(5):642-50. PubMed ID: 26873430
[TBL] [Abstract][Full Text] [Related]
12. Impact of disease activity and treatment of comorbidities on the risk of myocardial infarction in rheumatoid arthritis.
Meissner Y; Zink A; Kekow J; Rockwitz K; Liebhaber A; Zinke S; Gerhold K; Richter A; Listing J; Strangfeld A
Arthritis Res Ther; 2016 Aug; 18(1):183. PubMed ID: 27495156
[TBL] [Abstract][Full Text] [Related]
13. Malignancies and anti-TNF therapy in rheumatoid arthritis: a single-center observational cohort study.
Berghen N; Teuwen LA; Westhovens R; Verschueren P
Clin Rheumatol; 2015 Oct; 34(10):1687-95. PubMed ID: 26219489
[TBL] [Abstract][Full Text] [Related]
14. The Risk of Malignancy in Korean Patients with Rheumatoid Arthritis.
Lee H
Yonsei Med J; 2019 Feb; 60(2):223-229. PubMed ID: 30666845
[TBL] [Abstract][Full Text] [Related]
15. Risk of second malignant neoplasm and mortality in patients with rheumatoid arthritis treated with biological DMARDs: a Danish population-based cohort study.
Dreyer L; Cordtz RL; Hansen IMJ; Kristensen LE; Hetland ML; Mellemkjaer L
Ann Rheum Dis; 2018 Apr; 77(4):510-514. PubMed ID: 29217620
[TBL] [Abstract][Full Text] [Related]
16. Adherence of rheumatoid arthritis patients to biologic disease-modifying antirheumatic drugs: a cross-sectional study.
Mena-Vazquez N; Manrique-Arija S; Yunquera-Romero L; Ureña-Garnica I; Rojas-Gimenez M; Domic C; Jimenez-Nuñez FG; Fernandez-Nebro A
Rheumatol Int; 2017 Oct; 37(10):1709-1718. PubMed ID: 28631046
[TBL] [Abstract][Full Text] [Related]
17. Incidence of hip and knee replacement in patients with rheumatoid arthritis following the introduction of biological DMARDs: an interrupted time-series analysis using nationwide Danish healthcare registers.
Cordtz RL; Hawley S; Prieto-Alhambra D; Højgaard P; Zobbe K; Overgaard S; Odgaard A; Kristensen LE; Dreyer L
Ann Rheum Dis; 2018 May; 77(5):684-689. PubMed ID: 29247125
[TBL] [Abstract][Full Text] [Related]
18. Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs-a Swedish cohort study of risks by time, drug and lymphoma subtype.
Hellgren K; Di Giuseppe D; Smedby KE; Sundström C; Askling J; Baecklund E;
Rheumatology (Oxford); 2021 Feb; 60(2):809-819. PubMed ID: 32810256
[TBL] [Abstract][Full Text] [Related]
19. Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database.
Seror R; Lafourcade A; De Rycke Y; Pinto S; Castaneda J; Fautrel B; Mariette X; Tubach F
RMD Open; 2022 Jun; 8(2):. PubMed ID: 35738803
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis.
Jin Y; Desai RJ; Liu J; Choi NK; Kim SC
Arthritis Res Ther; 2017 Jul; 19(1):159. PubMed ID: 28679392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
